Chemistry Wealth Management’s T. Rowe Price Capital Appreciation Equity ETF TCAF Stock Holding History

Chemistry Wealth Management’s Portfolio TCAF Stock Details TCAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.98M	Buy	194,248 +10,049	+5%	+$397K	1.28%	15
2026 Q1	$6.56M	Buy	184,199 +5,964	+3%	+$223K	1.15%	17
2025 Q4	$6.81M	Buy	178,235 +14,711	+9%	+$564K	1.27%	15
2025 Q3	$6.16M	Buy	163,524 +8,435	+5%	+$308K	1.19%	16
2025 Q2	$5.47M	Buy	155,089 +12,562	+9%	+$412K	1.17%	16
2025 Q1	$4.6M	Buy	142,527 +14,916	+12%	+$500K	1.07%	18
2024 Q4	$4.25M	Buy	127,611 +17,251	+16%	+$582K	1%	19
2024 Q3	$3.67M	Buy	110,360 +16,382	+17%	+$525K	0.87%	22
2024 Q2	$2.95M	Buy	93,978 +35,498	+61%	+$1.08M	0.76%	25
2024 Q1	$1.77M	Buy	58,480 +36,348	+164%	+$1.05M	0.48%	39
2023 Q4	$612K	Buy	+22,132	New	+$573K	0.18%	83

Other funds holding TCAF

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

CPC

Consolidated Planning Corp Atlanta, Georgia $742M AUM 25.54% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

CCA

Cora Capital Advisors Marlton, New Jersey $356M AUM 27.17% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Cornerstone Advisory Hunt Valley, Maryland $1.21B AUM 19.13% 1-Year Est. Return

Chemistry Wealth Management's TCAF Position: Q2 2026 in Review

Chemistry Wealth Management increased its T. Rowe Price Capital Appreciation Equity ETF (TCAF) stake by 5.5% in Q2 2026, buying an estimated $397K and bringing the position to 194,248 shares worth $7.98M. The position accounts for 1.28% of the portfolio, ranked #15.

Chemistry Wealth Management first reported a position in TCAF in Q4 2023 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold TCAF as of Q2 2026.

Chemistry Wealth Management held 194,248 shares of T. Rowe Price Capital Appreciation Equity ETF worth $7.98M as of Q2 2026.
Chemistry Wealth Management bought 10,049 T. Rowe Price Capital Appreciation Equity ETF shares in Q2 2026, an estimated $397K.
T. Rowe Price Capital Appreciation Equity ETF made up 1.28% of Chemistry Wealth Management's portfolio in Q2 2026, its #15 holding.
Chemistry Wealth Management first reported a position in T. Rowe Price Capital Appreciation Equity ETF in Q4 2023 and has held it in 11 quarters since.
183 funds tracked by Wall St. Rank held T. Rowe Price Capital Appreciation Equity ETF as of Q2 2026.

Based on Chemistry Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.